Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478359 | 1.00 | PDE10A (0.52) | PDE10AKDM4EGPR3MAPTALDH1A1 | |
| SCHEMBL42594 | 0.75 | BCHE (0.53) | PDE10AKDM4EGPR3MAPTALDH1A1 | |
| SCHEMBL29559272 | 0.75 | BCHE (0.53) | PDE10AKDM4EGPR3MAPTALDH1A1 | |
| SCHEMBL197009 | 0.75 | PABPC1 (0.47) | MAPTMAPK1HTTLMNA | |
| SCHEMBL26919701 | 0.75 | HTT (0.44) | MAPTALDH1A1MAPK1HTTLMNA | |
| SCHEMBL31634338 | 0.75 | PABPC1 (0.47) | MAPTMAPK1HTTLMNA | |
| SCHEMBL29614829 | 0.74 | NPC1 (0.63) | PDE10AKDM4EGPR3MAPTALDH1A1 | |
| SCHEMBL29966674 | 0.74 | NPC1 (0.63) | PDE10AKDM4EGPR3MAPTALDH1A1 | |
| SCHEMBL29942654 | 0.74 | NPC1 (0.63) | PDE10AKDM4EGPR3MAPTALDH1A1 | |
| SCHEMBL3076524 | 0.74 | NPC1 (0.63) | PDE10AKDM4EGPR3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117721474-A | Cleaning agent for chip after chemical mechanical polishing, preparation method and application thereof | 江苏奥首材料科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-112939829-B | Synthetic method of aryl trifluoromethyl thioether | 武汉药明康德新药开发有限公司 | 2023-02-21 | — | — | CN | claimed |
| CN-112939829-A | Synthetic method of aryl trifluoromethyl thioether | 武汉药明康德新药开发有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-104262347-B | Blue-light semiconductor material containing two pyrazolo pyrenes and preparation method thereof and the organic luminescent device being made up of the material | 上海珂力恩特化学材料有限公司 | 2017-03-08 | — | — | CN | claimed |
| CN-105579042-A | Method for treating skin thickening | GALDERMA RES & DEV | 2016-05-11 | — | — | CN | claimed |
| CN-104288768-A | Use of alpha-adrenergic receptor agonist | GALDERMA RES & DEV | 2015-01-21 | — | — | CN | claimed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20250325547-A1 | ANTI-SARS-COV-2 DRUG | KAGOSHIMA UNIVERSITY (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250215019-A1 | ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2025098545-A1 | NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2025-05-15 | — | — | WO | disclosed |
| EP-4553080-A1 | NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2025-05-14 | — | — | EP | disclosed |
| CN-119564686-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2006092430-A1 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHASES | Universität des Saarlandes (DE) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006056608-A2 | CARBONYLATION PROCESS AND CATALYST THEREFOR | PHOENIX CHEMICALS LIMITED (GB) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006044823-A2 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| CN-1609105-A | 1-hydroxymethyl imidazo [1, 2-alpha ] quinoxaline compound and application thereof | INST OF TOXIC PHARMACOLOGY ACA (CN) | 2005-04-27 | — | — | CN | disclosed |
| US-6548499-B1 | N-(1-Azabicyclo(2.2.2)octanyl-3-pyridinyl)-3-(2-pyridinyl)-2 -quinoxalinamine, for example; treating various chemokine mediated diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| WO-1999042463-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
| EP-0030795-A2 | Quinoxaline derivatives, processes therefor, pharmaceutical compositions, and benzene derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215019-A1 | ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS | BMP2, BMP4, DCX | PDE10A 4536/4885KDM4E 2826/4885GPR3 3429/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | PDE10A 842/4885KDM4E 1315/4885GPR3 803/4885 |
| US-20250325547-A1 | ANTI-SARS-COV-2 DRUG | ACE2, ACE, AGTR2 | PDE10A 2971/4885KDM4E 1986/4885GPR3 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.